Patents by Inventor Lance G. Hammerland

Lance G. Hammerland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • G-protein fusion receptors and constructs encoding same
    Patent number: 7262280
    Abstract: The present invention features G-protein fusion receptors and chimeric GABAB receptors (GABABRs), nucleic acid encoding such receptors, and the use of such receptors and nucleic acid. G-protein fusion receptors comprise at least one domain from a CaR, an mGluR, and/or a GABAB receptor fused directly or through a linker to a guanine nucleotide-binding protein (G-protein). Chimeric GABABRs comprise at least one of a GABABR extracellular domain, a GABABR transmembrane domain, or a GABABR intracellular domain and one or more domains from a mGluR subtype 8 (mGluR8) and/or a CaR.
    Type: Grant
    Filed: October 3, 2000
    Date of Patent: August 28, 2007
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Thomas M. Stormann, Lance G. Hammerland, Laura L. Storjohann, James G. Busby, James E. Garrett, Rachel T. Simin
  • Human metabotropic glutamate receptor
    Patent number: 7241863
    Abstract: A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR, as well as compounds that modulate mGluR activity, may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: July 10, 2007
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Karen J. Krapcho, Thomas M. Stormann, Cynthia Levinthal, Lance G. Hammerland, Laura Storjohann
  • Novel human metabotropic glutamate receptor
    Publication number: 20030157647
    Abstract: A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Application
    Filed: January 17, 2003
    Publication date: August 21, 2003
    Inventors: Karen J. Krapcho, Thomas M. Stormann, Cynthia Levinthal, Lance G. Hammerland, Laura Storjohann
  • Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
    Publication number: 20030113873
    Abstract: The present invention provides chimeric receptors. The chimeric receptors comprise at least one region homologous to a region of a metabotropic glutamate receptor and at least one region homologous to a region of a calcium receptor. The invention also includes methods of preparing such chimeric receptors, and methods of using such receptors to identify and characterize compounds which modulate the activity of metabotropic glutamate receptors or calcium receptors.
    Type: Application
    Filed: November 19, 2002
    Publication date: June 19, 2003
    Applicant: NPS Pharmaceuticals
    Inventors: Forrest H. Fuller, Lance G. Hammerland, Karen J. Krapcho, Laura L. Storjohann, Thomas M. Stormann
  • Nucleic acids encoding mGLuR/CaR chimera
    Patent number: 6534289
    Abstract: The present invention provides chimeric receptors. The chimeric receptors comprise at least one region homologous to a region of a metabotropic glutamate receptor and at least one region homologous to a region of a calcium receptor. The invention also includes methods of preparing such chimeric receptors, and methods of using such receptors to identify and characterize compounds which modulate the activity of metabotropic glutamate receptors or calcium receptors. The invention also relates to compounds and methods for modulating metabotropic glutamate receptor activity and binding to metabotropic glutamate receptors. Modulation of metabotropic glutamate receptor activity can be used for different purposes such as treating neurological disorders and diseases, inducing an analgesic effect, cognition enhancement, and inducing a muscle-relaxant effect.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: March 18, 2003
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Forrest H. Fuller, Karen J. Krapcho, Lance G. Hammerland, Laura L. Storjohann, Thomas M. Stormann
  • Human metabotropic glutamate receptor
    Patent number: 6534287
    Abstract: A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: March 18, 2003
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Karen J. Krapcho, Thomas M. Stormann, Cynthia Levinthal, Lance G. Hammerland
  • Human metabotropic glutamate receptor
    Patent number: 6084084
    Abstract: A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: July 4, 2000
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Thomas M. Stormann, Rachel T. Simin, Lance G. Hammerland, Forrest H. Fuller
  • Human metabotropic glutamate receptor
    Patent number: 6077675
    Abstract: A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: June 20, 2000
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Thomas M. Stormann, Rachel T. Simin, Lance G. Hammerland, Forrest H. Fuller
  • Isolated human metabotropic glutamate receptor Mglur-8
    Patent number: 6051688
    Abstract: A human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR as well as compounds that modulate mGluR activity may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: April 18, 2000
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Thomas M. Stormann, Rachel T. Simin, Lance G. Hammerland, Forrest H. Fuller
  • Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors
    Patent number: 5981195
    Abstract: The present invention provides chimeric receptors. The chimeric receptors comprise at least one region homologous to a region of a metabotropic glutamate receptor and at least one region homologous to a region of a calcium receptor. The invention also includes methods of preparing such chimeric receptors, and methods of using such receptors to identify and characterize compounds which modulate the activity of metabotropic glutamate receptors or calcium receptors. The invention also relates to compounds and methods for modulating metabotropic glutamate receptor activity and binding to metabotropic glutamate receptors. Modulation of metabotropic glutamate receptor activity can be used for different purposes such as treating neurological disorders and diseases, inducing an analgesic effect, cognition enhancement, and inducing a muscle-relaxant effect.
    Type: Grant
    Filed: July 25, 1996
    Date of Patent: November 9, 1999
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Forrest H. Fuller, Karen J. Krapcho, Lance G. Hammerland